Synthetic Cardiac Stem Cells Plus Therapeutic Microparticles
A synthetic version of a cardiac stem cell has been developed that could offer therapeutic benefits comparable to those from natural stem cells.
Researchers from North Carolina State University, the University of North Carolina at Chapel Hill and First Affiliated Hospital of Zhengzhou University say the synthetic stem cells could reduce some of the risks associated with stem cell therapies and have better preservation stability. The technology is applicable to other types of stem cells.
Stem cell therapy works by promoting endogenous repair; that is, they aid damaged tissue in repairing itself by secreting paracrine factors, including proteins and genetic materials.
Effective But Risky
While stem cell therapies can be effective, they are also associated with some risks of both tumor growth and immune rejection. Also, the cells themselves are very fragile, requiring careful storage and a multi-step process of typing and characterization before they can be used.
Ke Cheng, associate professor of molecular biomedical sciences at NC State University, associate professor in the joint biomedical engineering program at NC State and UNC and adjunct associate professor at the UNC Eshelman School of Pharmacy, led a team in developing the synthetic version of a cardiac stem cell that could be used in off-the-shelf applications.
Cheng and his colleagues fabricated a cell-mimicking microparticle (CMMP) from poly (lactic-co-glycolic acid) or PLGA, a biodegradable and biocompatible polymer.
The researchers then harvested growth factor proteins from cultured human cardiac stem cells and added them to the PLGA. Finally, they coated the particle with cardiac stem cell membrane.
“We took the cargo and the shell of the stem cell and packaged it into a biodegradable particle,” Cheng says.
Works Like Deactivated Vaccine
When tested in vitro, both the CMMP and cardiac stem cell promoted the growth of cardiac muscle cells.
They also tested the cell-mimicking microparticle in a mouse model with myocardial infarction, and found that its ability to bind to cardiac tissue and promote growth after a heart attack was comparable to that of cardiac stem cells. Due to its structure, CMMP cannot replicate, reducing the risk of tumor formation.
“The synthetic cells operate much the same way a deactivated vaccine works,” Cheng says. “Their membranes allow them to bypass the immune response, bind to cardiac tissue, release the growth factors and generate repair, but they cannot amplify by themselves. So you get the benefits of stem cell therapy without risks.
We are hoping that this may be a first step toward a truly off-the-shelf stem cell product that would enable people to receive beneficial stem cell therapies when they’re needed, without costly delays.”
The synthetic stem cells are much more durable than human stem cells, and can tolerate harsh freezing and thawing. They also don’t have to be derived from the patient’s own cells.
Therapeutic microparticles functionalized with biomimetic cardiac stem cell membranes and secretome Nature Communications